CLINICAL STUDY
The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease
Udho Thadani, MD, FACC*,*,
William Smith, MD, FACC ,
Stephen Nash, MD, FACC ,
Neville Bittar, MD, FACC ,
Stephen Glasser, MD, FACC||,
Puneet Narayan, MD, FACC¶,
Richard A. Stein, MD, FACC#,
Sharon Larkin, RN**,
Arthur Mazzu, PhD**,
Robert Tota, MD, FACC,
Kenneth Pomerantz, PhD and
Pavur Sundaresan, MD, PhD**
* Oklahoma University, Health Sciences Center, and Veterans Affairs Medical Center, Cardiology Section, Oklahoma City, Oklahoma, USA
New Orleans Center for Clinical Research, New Orleans, Louisiana, USA
Syracuse Preventive Cardiology, Syracuse, New York, USA
Gemini Scientific, Madison, Wisconsin, USA
|| University of Minnesota, School of Public Health, Minneapolis, Minnesota, USA
¶ Veterans Affairs Medical Center, Washington, DC, USA
# Brooklyn Hospital Center, Department of Cardiology, Brooklyn, New York, USA
** Bayer Corporation, Department of Clinical Pharmacology, West Haven, Connecticut, USA
Bayer Corporation, Department of Medical Affairs, West Haven, Connecticut, USA
Bayer Corporation, Department of Scientific Relations, West Haven, Connecticut, USA
Manuscript received May 15, 2002;
revised manuscript received July 12, 2002,
accepted July 24, 2002.
* Reprint requests and correspondence: Dr. Udho Thadani, OUHSC, Cardiology, 920 SL Young, WP 3120, Oklahoma City, OK 73104, USA.
udho-thadani{at}ouhsc.edu
OBJECTIVES: The effect of vardenafil, a potent and highly selective phosphodiesterase-5 (PDE5) inhibitor, on symptom-limited exercise time, time to first awareness of angina, and time to ischemic threshold (ST-segment depression  1 mm from baseline) during exercise tolerance testing (ETT) was examined in patients with stable coronary artery disease (CAD).
BACKGROUND: Erectile dysfunction (ED) is common among men with CAD. PDE5 inhibition is increasingly the preferred treatment option for ED. However, the effect of PDE5 inhibition on exercise-induced ischemia in CAD patients has received limited prospective evaluation.
METHODS: In this double-blind, crossover, single-dose multicenter study, 41 men with reproducible stable exertional angina due to ischemic CAD received vardenafil 10 mg or placebo, followed by ETT (5 to 10 metabolic equivalents [METS], Bruce protocol) 1 h postdose. Sublingual nitrate use was prohibited for 24 h pre- and postexercise study days. End points included symptom-limited treadmill exercise time, time to first awareness of angina, time to ischemic threshold, and safety.
RESULTS: Relative to placebo, vardenafil 10 mg did not alter exercise treadmill time (427 ± 105 s vs. 433 ± 109 s, p = 0.39), or time to first awareness of angina (292 ± 110 s vs. 291 ± 123 s, p = 0.59), but significantly prolonged time to ischemic threshold (334 ± 108 s vs. 381 ± 108, p = 0.0004). At peak exercise, vardenafil 10 mg did not alter blood pressure, heart rate, or rate-pressure product relative to placebo. The most common adverse events (facial flushing and headache) were of mild or moderate intensity, and short-lived.
CONCLUSIONS: Vardenafil 10 mg did not impair the ability of patients with stable CAD to exercise at levels equivalent or greater than that attained during sexual intercourse (average of 2.5 to 3.3 METS).
|
Abbreviations and Acronyms
| | CAD | | coronary artery disease | | DBP | | diastolic blood pressure | | ECG | | electrocardiogram | | ED | | erectile dysfunction | | ETT | | exercise tolerance test | | METS | | metabolic equivalents | | MI | | myocardial infarction | | PDE5 | | phosphodiesterase-5 | | SBP | | systolic blood pressure |
|
This article has been cited by other articles:
|
|
|
|
 
J. W. M. Cheng and S. R. Berhane
Managing Erectile Dysfunction in Patients With Cardiovascular Diseases: The Efficacy and Safety of Phosphodiesterase-5 Inhibitors
American Journal of Lifestyle Medicine,
May 1, 2009;
3(3):
201 - 211.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G. Jackson
CHAPTER 15c Erectile Dysfunction
ESC Textbook of Cardiovascular Medicine,
January 1, 2009;
2(1):
med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. Caretti, P. Bianciardi, R. Ronchi, M. Fantacci, M. Guazzi, and M. Samaja
Phosphodiesterase-5 Inhibition Abolishes Neuron Apoptosis Induced by Chronic Hypoxia Independently of Hypoxia-Inducible Factor-1{alpha} Signaling
Experimental Biology and Medicine,
October 1, 2008;
233(10):
1222 - 1230.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Wilkins, J. Wharton, F. Grimminger, and H. A. Ghofrani
Phosphodiesterase inhibitors for the treatment of pulmonary hypertension
Eur. Respir. J.,
July 1, 2008;
32(1):
198 - 209.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. A. Borlaug, V. Melenovsky, T. Marhin, P. Fitzgerald, and D. A. Kass
Sildenafil Inhibits {beta}-Adrenergic-Stimulated Cardiac Contractility in Humans
Circulation,
October 25, 2005;
112(17):
2642 - 2649.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. K. Thethi, N. O. Asafu-Adjaye, and V. A. Fonseca
Erectile Dysfunction
Clin. Diabetes,
July 1, 2005;
23(3):
105 - 113.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Kloner
Cardiovascular Effects of the 3 Phosphodiesterase-5 Inhibitors Approved for the Treatment of Erectile Dysfunction
Circulation,
November 9, 2004;
110(19):
3149 - 3155.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Pomara, G. Morelli, S. Pomara, S. Taddei, L. Ghiadoni, N. Dinelli, F. Travaglini, M. Dicuio, N. Mondaini, A. Salvetti, et al.
Cardiovascular Parameter Changes in Patients With Erectile Dysfunction Using Pde-5 Inhibitors: A Study With Sildenafil and Vardenafil
J Androl,
July 1, 2004;
25(4):
625 - 629.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Morgentaler
A 66-Year-Old Man With Sexual Dysfunction
JAMA,
June 23, 2004;
291(24):
2994 - 3003.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. T. Russell, B. K. Khandheria, and A. Nehra
Erectile Dysfunction and Cardiovascular Disease
Mayo Clin. Proc.,
June 1, 2004;
79(6):
782 - 794.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. M Crowe and D. S Streetman
Vardenafil Treatment for Erectile Dysfunction
Ann. Pharmacother.,
January 1, 2004;
38(1):
77 - 85.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. M. Fox, U. Thadani, P. T.S. Ma, S. D. Nash, Z. Keating, M. A. Czorniak, H. Gillies, M. Keltai, and on behalf of the CAESAR I investigators
Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina
Eur. Heart J.,
December 2, 2003;
24(24):
2206 - 2212.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Reffelmann and R. A. Kloner
Therapeutic Potential of Phosphodiesterase 5 Inhibition for Cardiovascular Disease
Circulation,
July 15, 2003;
108(2):
239 - 244.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Vardenafil and the Cardiovascular Response to Exercise
Journal Watch Cardiology,
February 21, 2003;
2003(221):
6 - 6.
[Full Text]
|
|
|
|
